Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Suzhou Suncadia Biopharmaceuticals Co., Ltd..The latest application filed is for "use of anti-pd-1 antibody in combination with famitinib in preparation of drug for treating tumors".

Company Profile

9.9.14

Suzhou Suncadia Biopharmaceuticals Co., Ltd. - Suzhou, Jiangsu CN
Suzhou Suncadia Biopharmaceuticals Co., Ltd. - Jiangsu N/A CN
Suzhou Suncadia Biopharmaceuticals Co., Ltd. - Suzhou CN

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use Of Anti-pd-1 Antibody In Combination With Famitinib In Preparation Of Drug For Treating Tumors App 20220251203 - Zhang; Lianshan ; et al.	2022-08-11
PD-1 antibody, antigen-binding fragment thereof, and medical application thereof Grant 11,365,255 - Yuan , et al. June 21, 2	2022-06-21
Pharmaceutical Composition Of Prolyl Hydroxylase Inhibitor And Preparation Method Therefor App 20220160693 - Yang; Zhiliang ; et al.	2022-05-26
Use of Combination of Anti-PD-1 Antibody and VEGFR Inhibitor in Preparation of Drug for Treating Cancers App 20220119528 - Sun; Xing ; et al.	2022-04-21
Use Of Il-15 Protein Complex Joint Pd-l1 Antibody For Treating Tumor Diseases App 20220111008 - Sun; Xing ; et al.	2022-04-14
Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers Grant 11,208,484 - Sun , et al. December 28, 2	2021-12-28
Use Of Combined Treatment Of Pd-1 Antibody And Apatinib For Treating Triple Negative Breast Cancer App 20210363253 - WANG; Quanren ; et al.	2021-11-25
Method For Preparing Alkynyl Pyridine Prolyl Hydroxylase Inhibitor App 20210206720 - Lu; Gang ; et al.	2021-07-08
Stable Anti-pd-1 Antibody Pharmaceutical Preparation And Application Thereof In Medicine App 20210000954 - Li; Jie ; et al.	2021-01-07
Pd-l1 Antibody, Antigen-binding Fragment Thereof And Medical Application Thereof App 20200399375 - Qu; Xiangdong ; et al.	2020-12-24
PD-L1 antibody, antigen-binding fragment thereof and medical application thereof Grant 10,815,304 - Qu , et al. October 27, 2	2020-10-27
Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine Grant 10,786,567 - Li , et al. September 29, 2	2020-09-29
Medical Use Of Anti-c Met Antibody-cytotoxic Drug Conjugate App 20200054764 - SUN; Xing ; et al.	2020-02-20
Use of Combination of Anti-PD-1 Antibody and VEGFR Inhibitor in Preparation of Drug for Treating Cancers App 20200040078 - SUN; Xing ; et al.	2020-02-06
Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof Grant 10,543,284 - Liu , et al. Ja	2020-01-28
Stable Anti-pd-1 Antibody Pharmaceutical Preparation And Application Thereof In Medicine App 20180339045 - LI; Jie ; et al.	2018-11-29
Pd-l1 Antibody, Antigen-binding Fragment Thereof And Medical Application Thereof App 20180334504 - QU; Xiangdong ; et al.	2018-11-22
Anti-c-met Antibody And Anti-c-met Antibody-cytotoxic Drug Conjugate And Pharmaceutical Use Thereof App 20180110875 - LIU; Jiajian ; et al.	2018-04-26

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.